These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3051405)

  • 1. Marrow transplantation for hematologic malignancies: a brief review of current status and future prospects.
    Appelbaum FR
    Semin Hematol; 1988 Jul; 25(3 Suppl 3):16-22. PubMed ID: 3051405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute leukemia in adults with chemoradiotherapy and bone marrow transplantation.
    Appelbaum FR; Thomas ED
    Cancer; 1985 May; 55(9 Suppl):2202-9. PubMed ID: 3884138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic bone marrow transplantation in the treatment of hematologic diseases.
    Yee GC; McGuire TR
    Clin Pharm; 1985; 4(2):149-60. PubMed ID: 3886273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
    Nachbaur D; Schwaighofer H; Thaler J; Weyrer W; Fink M; Nussbaumer W; Fritsch E; Niederwieser D
    Wien Klin Wochenschr; 1994; 106(7):201-7. PubMed ID: 8197754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
    Giralt SA; LeMaistre CF; Vriesendorp HM; Andersson BS; Dimopoulos M; Gajewski J; Van Besien K; Mehra R; Przepiorka D; Khouri I
    J Clin Oncol; 1994 Sep; 12(9):1923-30. PubMed ID: 8083714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow transplantation for hematologic malignancies.
    Blume KG; Forman SJ
    J Cell Physiol Suppl; 1982; 1():99-102. PubMed ID: 7040422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow transplantation: a new treatment approach for Mississippians.
    Bigelow CL; Files JC
    J Miss State Med Assoc; 1991 Jun; 32(6):205-8. PubMed ID: 1870116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous bone marrow transplantation for leukemia.
    Stuart RK
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatched bone marrow transplantation in children with hematologic malignancy using T lymphocyte depleted bone marrow.
    Trigg ME; Sondel PM; Billing R; Finlay JL; Peterson A; Hong R; Frierdich S; Shahidi N
    J Biol Response Mod; 1985 Dec; 4(6):602-12. PubMed ID: 3910764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic recovery following autologous and allogeneic bone marrow transplantation.
    Harada M; Yoshida T; Ishino C; Matsue K; Kodo H; Mori T; Shiobara S; Odaka K; Ohtake S; Kondo K
    Exp Hematol; 1983 Oct; 11(9):841-8. PubMed ID: 6357827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Indications, technique and risks in bone marrow transplantation in adulthood].
    Heyll A; Söhngen D; Minning H; Meckenstock G; Aul C; Schneider W
    Praxis (Bern 1994); 1996 Mar; 85(12):378-86. PubMed ID: 8643901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New conditioning regimens for high risk marrow transplants.
    Jones RJ; Santos GW
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():15-7. PubMed ID: 2627618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.